Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Related ARIA
Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher
Mid-Day Market Update: Dow Jumps Over 200 Points; Staples Shares Surge On Confirmation Of Stake By Starboard Value
Wayfair Rises, Westport Innovations Cuts Forecast (Fox Business)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “With ponatinib approval for refractory/intolerant CML expected in U.S./EU in ~1Q13/3Q13, ARIA provided its commercial launch plan and a bit more details on ponatinib sales forecast, while refraining from providing profitability forecast (vs. our estimate of ~2016). Unlike ponatinib, AP26113 faces competition; we view its planned pivotal trial in ALK+ NSCLC in 2013 as important to maintain a competitive edge.”

Ariad Pharmaceuticals closed on Friday at $23.14.

Latest Ratings for ARIA

DateFirmActionFromTo
Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Get Benzinga's Newsletters